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Abstract
Identification and characterization of mutations that drive cancer evolution constitute a major focus of cancer research.
Consequently, dominant paradigms attribute the tumorigenic effects of carcinogens in general and ionizing radiation in
particular to their direct mutagenic action on genetic loci encoding oncogenes and tumor suppressor genes. However, the
effects of irradiation are not limited to genetic loci that encode oncogenes and tumor suppressors, as irradiation induces a
multitude of other changes both in the cells and their microenvironment which could potentially affect the selective effects
of some oncogenic mutations. P53 is a key tumor suppressor, the loss of which can provide resistance to multiple genotoxic
stimuli, including irradiation. Given that p53 null animals develop T-cell lymphomas with high penetrance and that
irradiation dramatically accelerates lymphoma development in p53 heterozygous mice, we hypothesized that increased
selection for p53-deficient cells contributes to the causal link between irradiation and induction of lymphoid malignancies.
We sought to determine whether ionizing irradiation selects for p53-deficient hematopoietic progenitors in vivo using
mouse models. We found that p53 disruption does not provide a clear selective advantage within an unstressed
hematopoietic system or in previously irradiated BM allowed to recover from irradiation. In contrast, upon irradiation p53
disruption confers a dramatic selective advantage, leading to long-term expansion of p53-deficient clones and to increased
lymphoma development. Selection for cells with disrupted p53 appears to be attributable to several factors: protection from
acute irradiation-induced ablation of progenitor cells, prevention of irradiation-induced loss of clonogenic capacity for stem
and progenitor cells, improved long-term maintenance of progenitor cell fitness, and the disabling/elimination of
competing p53 wild-type progenitors. These studies indicate that the carcinogenic effect of ionizing irradiation can in part
be explained by increased selection for cells with p53 disruption, which protects progenitor cells both from immediate
elimination and from long-term reductions in fitness following irradiation.
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Introduction
Exposure to ionizing radiation (including c or X rays) is strongly
associated with cancer etiology in humans and mouse models
[1,2]. Since cancer development requires the accumulation of
oncogenic mutations and mutagen exposure has been shown to
cause cancer, predominant paradigms attribute the carcinogenic
action of mutagenic carcinogens (including radiation) to the
induction of genetic and epigenetic alterations in oncogenes and
tumor suppressor genes [1,3,4]. On the other hand, various
investigators have proposed that carcinogenic treatments increase
the selective advantages conferred by certain oncogenic mutations,
thereby initiating tumorigenesis [5–9]. While ionizing irradiation
is an archetypal mutagenic carcinogen, the causal link between
induction of mutations in oncogenic loci and carcinogenesis is
mostly inferential. On the other hand, ionizing irradiation clearly
induces multiple changes both within cells and in their
microenvironment [1,10]. Thus, the carcinogenic effect of
irradiation might not be limited to causation of mutations in
cancer-related genes but may also be attributed to increased
selection for certain oncogenic events, which are either preexisting
or irradiation-induced.
P53 is a critically important tumor suppressor that mediates
responses to a variety of cellular stresses and has well-characterized
roles in mediating cell cycle arrest and apoptosis in response
to genotoxic stress [11]. The p53 gene is mutated in about half
of human tumors, and many tumors that retain wild-type (WT)
p53 contain mutations that disrupt p53 regulation. A number
of studies have documented that loss of p53 function confers a
survival advantage following c-irradiation in short-term survival
assays [11]. In particular, p53 confers a dramatic protection of
thymocytes from c-irradiation induced apoptosis in vivo [12–14].
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induced death and to loss of clonogenic potential [14–18]. On
the other hand, short-term resistance to genotoxic stress conferred
by p53 mutation often does not correlate with long-term
survival advantages [19], which might reflect the frequent
incompatibility of extensive DNA damage with long-term
survival.
Germline disruption of p53 in mice leads to lethal thymomas
and sarcomas with 100% penetrance [20–22]. While c-irradiation
accelerates development of malignancies in newborn p532/2
mice, this acceleration is not seen in adult p532/2 mice [23].
However, irradiation dramatically accelerates tumorigenesis in p53
heterozygous (+/2) adult mice, and most of the resulting tumors
exhibit loss of the second p53 allele [23], suggesting that loss of p53
function may be selected for following irradiation. Alternatively,
the acceleration of thymoma development in p53+/2 mice by
irradiation might be explained by the promotion of loss-of-
heterozygosity at the p53 locus or by the induction of oncogenic
mutations, in either case due to the mutagenic effects of
irradiation. This latter possibility is supported by the observation
that many oncogenic mutations that normally activate apoptotic
or senescence responses can drive strong proliferation in cells with
disrupted p53 function [24].
The relative importance for induction versus selection of
oncogenic mutations in the carcinogenic action of irradiation
remains poorly explored. In particular, whether the causal link
between radiation exposure, p53 disruption, and cancers involves
selection for p53 loss or depends entirely upon irradiation-induced
mutagenesis at loci encoding proliferation control genes remains
unresolved. To address this question, we analyzed the impact of
irradiation on the selective effect of p53 disruption in a minor
fraction of hematopoietic progenitor cells within predominantly
WT hematopoietic pools. This approach models the physiological
context whereby malignancies are initiated by rare cells with
oncogenic mutations. Our experiments demonstrate that following
irradiation, p53 loss provides an immediate and sustained selective
advantage in all hematopoietic lineages, which translates into
greater expansion of p53-deficient clones and increased lymphoma
development.
Results
Irradiation Selects for p53 Disruption in Hematopoietic
Cells
To address the impact of irradiation on selection of cells with
dysfunctional p53, we generated mice with mosaic hematopoietic
systems, containing a small percentage of cells with disrupted p53
activity and co-expressed GFP (Figure 1A). To do so, we
transplanted bone marrow (BM) progenitors transduced with low
titer MSCV-ires-GFP retroviruses (MiG) encoding DDp53 (or
empty vector controls) into lethally irradiated recipients. DDp53
encodes for the multimerization domain of p53 (amino acids 302-
390), and expression of DDp53 leads to potent inhibition of
endogenous p53 activity [25,26]. The transplanted animals were
allowed to recover for 6 wk, at which point hematopoiesis was
restored with relatively normal peripheral leukocyte counts
(unpublished data). At this point, roughly 2% of the cells were
GFP
+ both in myeloid and B-cell lineages (Figure 1B, time 0).
Thus, this model creates a context wherein the fate of a small
percentage of p53 disrupted hematopoietic progenitors can be
monitored in an otherwise WT background and that also
eliminates potential effects of p53 deficiency in non-hematopoietic
tissues [27,28].
The mice were then sub-lethally X-irradiated (2.5 Gy), and the
percentage of transduced (GFP
+) cells was monitored over 4 wk in
peripheral blood cells. The percentages of DDp53 transduced cells
(GFP
+) in the non-irradiated controls remained stable (Figure 1B;
control groups), indicating that p53 disruption does not provide a
substantial advantage during normal steady state hematopoiesis.
In contrast, irradiation led to a significant increase in the
percentages of DDp53 cells, as average percentages of GFP
+ cells
increased 5-fold in the myeloid (Mac1
+ cells) lineage and 3.5-fold
in the B cell (B220
+ cells) lineage (Figure 1B; irradiated groups).
Examples of flow cytometric profiles are shown in Figure S1.
Given that irradiation had no effect on the expansion of vector
transduced cells, inhibition of p53 activity is advantageous to
hematopoietic cells upon or after irradiation. An advantage
conferred to early progenitors but not mature myeloid cells post-
irradiation may account for the delayed rise in the percentages of
myeloid cells expressing DDp53 starting at Week 2. As for the
MAC1
+ and B220
+ lineages, irradiation caused increases in the
percentages of DDp53 cells in the CD4
+ and CD8
+ T cell lineages
(Figure 1C).
To confirm these findings using a different model of p53
disruption, we created BM chimeric mice containing cells with null
genetic disruption of both p53 alleles. For these experiments, the
null p53 allele [21] was bred into a transgenic (Tg) line that
expresses GFP in all tissues from the Ubiquitin-C promoter [29].
We generated mosaic mice by transplantation of lethally irradiated
recipients with WT BM mixed 7:1 with either p53+/+ or p532/2
GFP Tg BM. After hematopoiesis was allowed to recover for 6 wk,
the mice were sublethally irradiated (2.5 Gy) and competitive
hematopoiesis was observed by monitoring peripheral blood over
the next 4 wk (Figure 2A). Similar to our results with DDp53
transduced cells, irradiation led to a dramatic selection for
Author Summary
Cancer progression can be understood through the
framework of Darwinian evolution, which involves two
major factors: genetic mutation and selection. Random
mutations are thought to result in the initiation and
phenotypic diversification of tumors, and environmental
influences mediate selection for those mutations that
increase tumor cell fitness. Since oncogenic mutations are
necessary for the development of spontaneous malignan-
cies and since experimental introduction of these muta-
tions often leads to transformation and cancers, the
causation of cancers by carcinogens is traditionally
attributed to their induction of new mutations that are
oncogenic. We instead asked whether selection for
oncogenic mutations is affected by ionizing irradiation,
an archetypal mutagenic carcinogen, by examining the
selective effects of inactivation of the critical tumor
suppressor gene p53. While disruption of p53 is selectively
neutral in populations of unstressed hematopoietic
progenitors, it provides a strong selective advantage upon
irradiation. This selection of p53-deficient clones is
attributable to protection from irradiation-induced cell
death and loss of cellular fitness. Importantly, the selective
expansion of irradiated cells bearing p53 disruption is
blocked in the presence of non-irradiated wild-type
competitors, indicating that the disabling of competing
wild-type cells by irradiation is critical for selection of p53-
deficient cells. Our results argue that induction of cancers
by irradiation involves selection for mutations that confer
radioresistance, and suggest that greater focus on how
carcinogenic contexts impact on selection is warranted in
understanding, preventing and treating cancers.
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Figure 1. X-irradiation selects for hematopoietic progenitors expressing DDp53. Freshly isolated BM was transduced with MiG (Vector) or
MiG-DDp53 and transplanted into lethally irradiated recipients (schemata in A). Initial transduction efficiency was 3.8% for the vector and 3.2% for the
DDp53 transduced cells. 1610
7 cells were transplanted per recipient. Six weeks post-transplantation, blood was drawn for the baseline analysis
(0 wk). Subsequently, five recipients of vector transduced BM and 10 recipients of DDp53 transduced BM were X-irradiated with a single 2.5 Gy dose,
and five vector and five DDp53 mice were left untreated. (B) At 1, 2, and 4 wk post-irradiation, peripheral blood was analyzed for the expression of
GFP in MAC
+ myeloid and B220
+ B-lineage cells. (C) At 55 d post-irradiation, GFP expression in peripheral blood CD4
+ and CD8
+ T cells was analyzed
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+ and B220
+ lineages, resulting in a
virtual selective sweep of the p53 mutation within the hematopoi-
etic systems of most recipient animals (Figure 2B). No increase in
the percentage of p53 null cells, beyond those expected based on
initial ratios transplanted, was evident within unirradiated
hematopoiesis.
Irradiation of recipient mice also led to dramatic increases in the
percentages of p532/2 cells in the CD4
+ and CD8
+ T cell lineage
(Figure 2C). But in contrast to retrovirally delivered DDp53, we
also observed modest selection for p532/2 cells in non-irradiated
CD4
+ and CD8
+ cells, which could either reflect the pre-existence
of partially transformed p532/2 cells in the T-cell lineage
(consistent with eventual T lymphoma development) or skewed
selection for p532/2 T progenitors in the abnormal thymic
environment of irradiated recipient mice.
Irradiated recipients of 7:1 WT:p532/2 BM developed
thymomas and T cell leukemias with high penetrance, while
development of malignancies in the unirradiated group was
significantly reduced and delayed (Figure 2D). All malignancies
that developed with or without irradiation expressed GFP and thus
were derived from the GFP Tg p532/2 donor BM (Figure S2). As
expected, recipients of WT BM did not develop thymomas, with
or without irradiation, as a single dose of radiation is not sufficient
to induce lymphomas within this time frame.
P53 Disruption Protects Hematopoietic Progenitors from
Irradiation-Induced Ablation
To assess whether p53 disruption provides an immediate
survival advantage following irradiation, we analyzed hematopoi-
etic tissues at 48 h post-irradiation, focusing on hematopoietic
progenitor populations, whose relative survival should determine
effects on long-term selection. We used the same experimental
design described in Figure 2A, except that a 19:1 mixture of
WT:p532/2 GFP BM was transplanted. At 48 h, cells that were
killed by direct irradiation-induced damage should have been
cleared, while the extent of new proliferation should still be
minimal. Irradiation of these chimeric mice at 2.5 Gy had a
substantial negative effect on the hematopoietic system, leading to
approximately 4-fold reductions in BM cellularity and 2-fold
reductions in spleen weight (Figure S3). Yet the impact of
irradiation was not equivalent for different hematopoietic lineages.
B lineage cells were more radiosensitive than myeloid lineage cells:
while BM myeloid cells were reduced in number by about 8-fold,
the total BM B220
+ population was reduced about 30-fold, and
BM pro-B and pre-B progenitor populations were reduced 40–60-
fold (Figures 3A, S4, and S5A).
Accordingly, irradiation caused substantial increases in the
percentages of p532/2 cells in the pre-B and pro-B populations
(Figures 3B and S5A), as well as in total B220
+ population (Figure
S4). Similar results were obtained at 48 h post-irradiation for
recipients of BM where p53 disruption was mediated by
expression of DDp53 (unpublished data). Importantly, irradiation
reduced the numbers of not only WT but also p532/2 pre-B and
pro-B cells (Figures 3A and S5A). However, the reduction of
p532/2 B progenitor numbers was clearly less extensive.
Therefore, p53 disruption provides partial radioprotection.
Examples of flow cytometric profiles for detection of GFP
expression in myeloid, pre-B, and pro-B cell populations are
shown in Figure S6.
CD4
+CD8
+ (double-positive; DP) T cell progenitors in the
thymus are known to be very sensitive to irradiation-induced
apoptosis [12,13]. Indeed, at 48 h post-irradiation we observed
dramatic ablation of the DP population, while single-positive cells
remained relatively unaffected (Figure S7). Similarly to B cell
progenitors, disruption of p53 provided a clear radioprotective
effect in thymic T-cell progenitors, as irradiation led to increased
percentages of p532/2 cells in the DP population (Figure 3B).
Again, this radioprotection was not absolute: while the numbers of
WT GFP
+ DP cells dropped about 28-fold following irradiation,
the numbers of p532/2 GFP
+ DP cells dropped about 7-fold
(Figure 3A, right plot). As also observed in experiments shown in
Figure 2, for the T cell lineage, p53 loss may confer some
advantage even without irradiation, as p532/2 percentages
increased in DP cells in non-irradiated controls relative to pre-
irradiation, and thus the irradiation induced increase in the
percentage of GFP
+ p532/2 DP cells is less evident than in other
lineages (Figure 3B, right plot).
We next examined the effect of irradiation on hematopoietic
stem cells (HSC) by examining the HSC-enriched CD150
+ Lin
neg/
CD48
neg BM compartment [30]. In contrast to the lymphoid
progenitor pools, CD150
+ Lin
neg/CD48
neg cell numbers were not
affected by irradiation, and we did not observe changes in the
percentages of p532/2 cells (Figures S5B and S6E). Therefore,
disruption of p53 does not appear to provide an immediate
survival advantage in HSC pools.
P53 Disruption Preserves Clonogenic Capacity for
Irradiated Hematopoietic Progenitor and Stem Cells
Protection from immediate irradiation-induced ablation does
not necessarily correlate with maintenance of long-term prolifer-
ative capacity [19]. Therefore, we assessed the impact of p53
disruption on maintenance of clonogenic capacity by progenitor
and stem cells. To this end, p53+/+ or 2/2 mice were irradiated
(2.5 Gy) and BM was harvested 48 h later. Note that X-irradiation
resulted in a ,5-fold reduction in BM cellularity by 48 h for WT
mice but only ,2-fold reduction for p532/2 mice (Figure 4A).
BM cells were isolated from p53+/+ or 2/2 mice 48 h post-
irradiation, and either plated in methylcellulose cultures for
determination of colony forming units in vitro (CFU-GEMM for
granulocytic/erythroid/megakaryocyte/macrophage progenitors
or CFU-B for B-lymphoid progenitors) or transplanted into
lethally irradiated mice for determination of CFU in spleens
(CFU-S, derived from early multipotent progenitors) [31].
Consistent with the analyses above, irradiation resulted in
dramatic reductions in CFU-GEMM, CFU-B, and CFU-S
numbers (from 206 to 1006; Figure 4B), and p53 disruption
provided substantial protection from irradiation-induced elimina-
tion of these progenitors (numbers were reduced only 2–3-fold).
To determine the p53-dependent impact of irradiation on
numbers of functional HSC, we performed limiting dilution assays.
Varying numbers of ‘‘test’’ cells (control or 48 h post-irradiation)
were transplanted into lethally irradiated recipient mice, together
with a fixed number of competitors to ensure radioprotection.
Since irradiation can dramatically reduce the competitive ability of
HSC [32], we used competitor BM harvested from previously
(a later time point is analyzed, as production of significant mature T cells requires at least 6 wk post-irradiation). The ‘‘neg’’ data points are from mice
that received no transplantation, which serve as negative controls for GFP detection. For B, the indicated p values are for t tests comparing means of
changes in GFP percentages (baseline to 4 wk post-irradiation) between irradiated and control groups. For C, p values are for the comparison of the
changes in GFP percentages upon irradiation between vector and DDp53 groups.
doi:10.1371/journal.pbio.1000324.g001
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Figure 2. Irradiation selects for p532/2 hematopoietic progenitors. Freshly harvested WT BM was mixed with GFP Tg BM (WT control) or
GFP Tg p532/2 BM at 7:1 proportions and then transplanted into recipients that had been conditioned with 5 Gy irradiation (schemata in A). Each
recipient received a total 8610
6 BM cells. Six weeks post-transplantation, five WT control recipients and 14 p532/2 recipients were irradiated with 2.5
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irradiated ‘‘test’’ HSC are not masked by non-irradiated
competitors. In contrast to the lack of irradiation-induced ablation
of phenotypically defined HSC (as detected by flow cytometry;
Figures S5B and S6E), we observed dramatic reductions in the
frequencies of functional WT HSC but not p532/2 HSC,
following irradiation (Figure 4C). Considering the p53-depen-
dence of the effects of irradiation on BM cellularity (Figure 4A),
the loss of p53 confers substantial protection from irradiation-
induced reductions of functional HSC numbers per mouse.
In summary, the selective advantage for p53 disruption is
evident within 48 h in both long- and short-term progenitor
populations, supporting a direct role for p53 in radiation-induced
cell death. Moreover, beyond preventing the immediate death of
stem and progenitor cells following irradiation, the loss of p53
provides an additional selective advantage through protecting
clonogenic capacity.
P53 Disruption Partially Protects Hematopoietic
Progenitors from Irradiation-Induced Persistent
Reductions of Functional Capacity
Experiments described above demonstrate that loss of p53
protects cells from the acute effects of irradiation by preserving cell
survival as measured by phenotypic and functional assays.
However, the impact of irradiation is not limited to acute damage.
We and others have demonstrated that hematopoietic progenitors
suffer from impaired functional capacity long after the acute effects
of irradiation have been reversed; i.e., irradiation-induced loss of
functional capacity appears to be permanent [32,33]. We therefore
asked whether p53 disruption protects hematopoietic progenitors
from this long-term reduction of functional capacity. To this end,
we irradiated WT and p53 null mice, allowed them to recover for
6 wk, and used BM harvested from these mice to set up
competitive transplantation experiments with non-irradiated
GFP
+ BM cells at 19:1 ratios (p532/2:GFP or WT:GFP). By
6 wk post-irradiation, BM cellularity and the numbers of early
progenitors are restored [32], and thus these assays measure the
impact of p53 disruption on stable reductions of fitness per
progenitor caused by irradiation, as opposed to the immediate
physical or functional elimination of hematopoietic progenitors.
At 3 wk post-transplantation, the percentages of non-irradiated
GFP
+ cells had increased well beyond the initial 5% in the
transplanted mixture for both the p532/2:GFP or WT:GFP
groups (Figure 5A), reflecting impaired hematopoietic fitness in
previously irradiated BM. Still, irradiated p532/2 cells fared
substantially better than WT cells against unirradiated GFP
+
competitors as assessed both in the myeloid lineage (GR1
+) and in
total peripheral blood cells (Figure 5A; ,70% of hematopoiesis
was still p532/2). At 12 wk post-irradiation, however, non-
irradiated competitors completely took over the myeloid lineage,
irrespective of the p53 status of the irradiated donor BM, as the
percent GFP
+ within the myeloid lineage was indistinguishable
from recipients reconstituted with GFP
+ BM only (‘‘GFP’’ groups).
Still, p532/2 cells maintained a substantial presence within the
B220 lineage, while WT GFP-negative competitors could not be
detected.
Thus, loss of p53 failed to completely prevent irradiation-
induced loss of fitness of stem/progenitor cells as compared to the
fitness of non-irradiated WT cells. However, more relevant to
irradiation-induced selection is the selective advantage of mutant
cells relative to similarly irradiated WT cells. Therefore, we
directly compared the fitness of previously irradiated p532/2 and
WT cells, using an experimental design similar to that used in
Figure 5A, but this time using 1:1 ratios. As controls, we used 1:1
mixtures of BM isolated from non-irradiated p532/2 and WT
donors. As shown in Figure 5B, previously irradiated p532/2 BM
was clearly more competitive when measured against irradiated
WT BM, both in myeloid and lymphoid lineages (Figure 5B, red
bars). In contrast, the selective advantage for p53 disruption is
much less obvious in recipients of non-irradiated BM mixtures
(Figure 5B, blue bars). These results indicate that while loss of p53
is unable to completely protect cells from irradiation-induced loss
of fitness, p53 deficiency is still capable of endowing a clear
competitive advantage relative to irradiated WT cells. We
therefore conclude that in addition to protection from irradia-
tion-induced ablation, protection from persistent loss of fitness
contributes to selection for p53-deficientclones by irradiation.
Disruption of p53 in BM Cells after Recovery from
Irradiation Does Not Confer a Durable Selective
Advantage
Experiments described above demonstrate that when disrupted
at the time of irradiation, p53 loss provides a strong and sustained
selective advantage in hematopoietic stem/progenitor cells. We
asked whether disruption of p53 is still selectively advantageous
when introduced after the acute effects of irradiation have been
resolved. To address this question, we introduced DDp53 or
empty vector into BM progenitors harvested from donors that had
been irradiated 6 wk prior to the harvest (or control donors) and
transplanted the transduced BM into lethally irradiated recipients
(Figure 6A). While transduction efficiency was similar to
experiments described in Figure 1, disruption of p53 failed to
provide cells with a long-term selective advantage. We consistently
observed statistically significant overrepresentation of DDp53
expressing cells in the B-cell lineage at 3 wk post-transplantation
(Figure 6B); however, this advantage was no longer apparent at
8 wk post-transplantation. Thus, the observed transient advantage
for p53 disruption in the B-cell lineage may reflect an advantage in
short-term progenitors that is only evident during the reconstitu-
tion phase post-irradiation. Importantly, even at 21 wk post-
transplantation, we did not detect increased expansion of DDp53
expressing cells in either non-irradiated or irradiated hematopoi-
esis, despite the clear presence of a low percentage of GFP
+ cells in
multiple hematopoietic lineages in most recipients (Figure 6C).
The continued presence of GFP
+ cells in multiple lineages more
than 4 mo post-transplantation indicates that retroviral delivery of
Gy, while five recipients from the WT control and nine recipients from the p532/2 groups were left untreated (control). (B) At 1, 2, and 4 wk post-
irradiation peripheral blood was analyzed for the expression of GFP in MAC
+ myeloid cells and B220
+ B-cells. (C) At 7 wk post-irradiation, GFP
expression in peripheral blood CD4
+ and CD8
+ T cells was analyzed. For B and C, the ‘‘GFP’’ control reflects analyses of GFP expression in the indicated
lineages for peripheral blood from recipients transplanted with 100% GFP Tg BM. For B and C, p values are for t tests comparing means of base-line to
4 wk post-irradiation differences in GFP percentages between irradiated and control groups. (D) The same mice were followed for the development
of hematopoietic malignancies. Mice were sacrificed when moribund at the indicated times post-BM transplantation (BMT). All sacrificed mice
exhibited clear signs of GFP
+ p532/2 thymomas or leukemias. Most mice exhibited greatly enlarged thymi almost entirely composed of CD4
+CD8
+ or
CD4
+ GFP
+ blasted cells, together with infiltration of the spleen. The other sacrificed moribund mice exhibited a leukemic phenotype, with CD4
+CD8
+
or CD4
+ GFP
+ blast cell infiltration of the spleen and BM but without clear thymic enlargement. Kaplan-Meier curves for lymphoma-free survival are
plotted. The p value indicates the result of log-rank test analysis.
doi:10.1371/journal.pbio.1000324.g002
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Figure 3. Loss of p53 protects from acute irradiation-induced ablation. BM chimeric mice containing ,5% GFP Tg BM (WT) or ,5% GFP Tg
p532/2 BM were generated using the same experimental procedures described in Figure 2, except that a 19:1 ratio of WT BM to GFP Tg BM (WT or
p532/2) was used. Each recipient received a total 5610
6 BM cells. At 48 h post-2.5 Gy sublethal irradiation (IR), the mice were euthanized, and GFP
expression was analyzed in the indicated cell populations in the BM and thymi. ‘‘C’’ control mice were not irradiated. (A) The numbers of GFP
+ Mac1
+
myeloid cells and GFP
+ B220
+CD93
+CD43
negMac1
neg pre-B cells in the BM, and GFP
+ CD4
+CD8
+ DP cells in the thymus, were determined by
multiplying the percentage of these subsets among nucleated cells in the BM or thymus times the total number of nucleated cells determined for
one tibia or the thymus of each mouse. (B) Percentages of GFP
+ cells within the indicated lineages are graphed. For (A) and (B), p values for t tests
comparing differences between irradiation-induced changes in GFP percentages or cell numbers between WT and p532/2 groups are indicated.
doi:10.1371/journal.pbio.1000324.g003
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was not adaptive (i.e., advantageous) within irradiated HSC or
more committed progenitors.
We therefore conclude that p53 loss does not provide a selective
advantage after the acute effects of irradiation are resolved, and
thus selection for p53 mutant clones requires that p53 function is
defective at the time of irradiation.
Competition from Non-Irradiated Cells Blocks the
Selective Expansion of Irradiated p53-DeficientClones
The experiments described above argue that the selective
advantage of p53 loss at the time of irradiation is attributable to
protection of p53-deficient progenitors from immediate ablation,
loss of clonogenic capacity, and sustained fitness reductions.
However, it is possible that selection for p53 deficiency is in part
due to additional oncogenic events that are induced by irradiation
and whose ability to drive uncontrolled proliferation is permitted
by the lack of p539s critical tumor suppressive function [24].
Should this be the case, then one would expect that once a cell has
acquired the ability for uncontrolled proliferation, this clone will
expand whether or not competing cells were irradiated.
However, experiments presented in Figure 5A argue against this
scenario, as unirradiated competitors are capable of effectively
outcompeting irradiated p53 null cells. In these experiments,
competition was initiated after recovery from the acute effects of
irradiation. To determine the effects of non-irradiated competitors
on the acute irradiation-dependent selection for p53 loss, we asked
whether non-irradiated competitors, added immediately after
irradiation, can counter the selective effect of p53 disruption. To
this end, we used an experimental design similar to the one
presented in Figure 1. Consistent with results described in Figure 1,
DDp53 expression conferred a clear selective advantage in
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Figure 4. p53 loss protects progenitors from irradiation-induced loss of clonogenic potential. BM was harvested from non-irradiated or
irradiated (48 h previously at 2.5 Gy) WT or p53
2/2 mice and counted in triplicate (A; n.5/group). (B) CFU-B, CFU-GEMM, and CFU-S assays were
performed as described in Materials and Methods. For CFU-B and CFU-GEMM, colonies were counted 7 or 12 d later, respectively, and the numbers of
CFU per mouse (both femurs and tibiae) were calculated. Data reflect experiments performed in triplicate. CFU-S (per both femurs and tibiae of donor
mice) were enumerated after 14 d in spleens of recipient mice. Data are combined from two experiments with at least four recipients per group. (C)
BM was harvested from GFP-Tg mice that had either been irradiated 48 h before with 2.5 Gy or left untreated (the ‘‘test’’ cells). Different numbers of
viable GFP
+ test cells (0.25610
4 to 1610
5) were mixed with 10
6 viable competitor Balb/c (GFP
neg) BM cells isolated from donors that were irradiated
8 wk prior with 5 Gy. The mixes were injected into lethally irradiated Balb/c recipients. At 3–4 mo post-transplant, peripheral blood was stained with
PE-Cy7-anti-Mac1 plus PE-anti-B220 antibodies, and the percentages of GFP
+ cells in the MAC1
+ and B220
+ lineages were determined. The numbers
of functional HSC were determined based on the ability of different doses of BM to contribute to hematopoiesis in both the myeloid (Mac1
+) and B-
cell (B220
+) lineages (with $1.0% contribution required to be scored as positive). The numbers of functional HSC were determined with the L-Calc
TM
software from Stem Cell Technologies and are graphed as HSC frequencies per mouse (both femurs plus both tibiae). Four experiments are
combined. p values indicate the results of two-tailed ratio of proportions test.
doi:10.1371/journal.pbio.1000324.g004
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irradiated competitors completely prevented this selection
(Figure 7A).
We performed similar experiments using mice with chimeric
p532/2 hematopoiesis. As expected, irradiation resulted in strong
selection for p532/2 cells in multiple peripheral blood lineages
(Figure 7B). Similar to the results seen with inhibition of p53 by
DDp53, non-irradiated competitors potently inhibited this expan-
sion, which is particularly evident in the myeloid and B-cell
lineages. As the myeloid lineage is most responsive to changes in
HSC pools [34], these data indicate that non-irradiated compet-
itors can reverse selection for p53 disruption within irradiated
early progenitor pools. That the effect of competitors on T-
lymphoid lineages is more delayed and less dramatic is consistent
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Figure 5. p53 mutation present at the time of X-irradiation provides a long-term fitness advantage during competitive
reconstitution. (A) 1.5 mo WT and p532/2 mice were irradiated with 5 Gy. Six wk post-irradiation, BM was harvested, mixed with non-irradiated
GFP
+ BM at 1:19 GFP
+/WT or GFP
+/p532/2 ratios, and transplanted into lethally irradiated WT recipients. Each recipient received a total of 1610
7 BM
cells. The animals were bled at 3 and 12 wk post-transplantation and percentages of GFP
+ cells were determined in either the myeloid lineage
(‘‘GR1
+’’) or in total nucleated blood cells (‘‘total’’). Note that the y-axis for this figure represents contributions from non-irradiated GFP-Tg BM. The
‘‘GFP’’ data points represent analyses of peripheral blood from control recipients of 100% GFP Tg BM (some GFP
neg cells are detected even in these
recipients, which could reflect residual host cells). (B) Six-week-old GFP
+ WT and GFP
neg p532/2 mice were irradiated with 5 Gy or left non-irradiated.
1.5 month post-irradiation, BM was harvested and viable cells were mixed in 50:50 proportions and transplanted into lethally irradiated recipients to
yield two experimental groups (n=5 each): unirradiated GFP
+ WT plus unirradiated GFP
neg p532/2 (blue bars) and irradiated GFP
+ WT plus irradiated
GFP
neg p532/2 (red bars). Peripheral blood was analyzed for GFP expression in the indicated lineages at 3 and 12 wk post-transplantation. The
dashed line indicates the expected 50% contribution from GFP Tg hematopoiesis if the fitness of the competing p532/2 hematopoiesis were
identical. Results are shown for mixes where WT cells are GFP Tg, but similar results were obtained for reciprocal mixes whereby p532/2 cells were
GFP Tg (unpublished data).
doi:10.1371/journal.pbio.1000324.g005
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Figure 6. p53 disruption after recovery from the acute effects of irradiation does not provide a selective advantage. (A) BM was
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6 donor BM cells. (B) Peripheral blood was analyzed for GFP expression in MAC1
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progenitors. We therefore conclude that selection for p53
deficiency by irradiation does not depend on acquisition of
additional oncogenic hits in the p53-deficient cells.
We next asked whether inhibiting selection for p532/2
progenitors by transplantation of non-irradiated competitors
translates into reduced incidence of p532/2 thymomas. The
cohorts of recipient mice depicted in Figure 7B were monitored for
tumor development. As before (Figure 2D), the irradiation of
chimeras containing a minor fraction of p532/2 hematopoiesis
resulted in substantial promotion of p532/2 thymoma develop-
ment (Figures 8A and S2). Surprisingly, transplantation of non-
irradiated competitor BM after sublethal irradiation only modestly
delayed p532/2 thymoma development, and this delay was not
statistically significant. Notably, in contrast to the myeloid and B-
cell lineages, we observed a substantial delay in the ability of non-
irradiated hematopoiesis to displace irradiated p532/2 T-lineage
cells (Figure 7B). Therefore, a large pool of p532/2 T-progenitors
might be maintained for a sufficient period of time to enable the
occurrence of transforming secondary oncogenic events, thus
underlying the failure of the non-irradiated transplant to effectively
prevent thymoma development.
Alternatively, if the causal link between irradiation and
tumorigenesis from p532/2 cells does not involve the selection
of radioresistant p53 null cells, and instead completely relies on the
mutagenic action of irradiation, then irradiation should enhance
development of T-cell lymphomas in mice with non-chimeric
p532/2 hematopoietic systems. When essentially all hematopoi-
etic cells are p532/2 mutant, the contribution of selection for p53
null cells toward tumorigenesis should be negated. Thus, we
transplanted radio-conditioned recipients with p532/2 BM and
allowed their hematopoietic systems to return to equilibrium (at
which point almost all hematopoiesis was donor-derived and thus
p532/2). We then split the mice into irradiation and control
groups and followed the development of lymphomas after
irradiation. Contrary to the predicted mutagenic mechanism of
irradiation induced tumorigenesis, irradiation not only failed to
enhance the development of T-cell malignancies but actually
impeded their development, extending the mean survival of the
mice (Figure 8B).
In summary, our results demonstrate that irradiation strongly
selects for p53-deficientcells in pools of stem and progenitor cells
and that this selection does not rely on acquisition of additional
oncogenic mutations. These studies instead indicate that altered
selection for p53 loss contributes to the causal links between
irradiation, p53 disruption, and tumorigenesis.
Discussion
Dominant paradigms attribute the induction of cancers by
DNA-damaging carcinogens (including ionizing radiation) to their
mutagenic actions, in that these agents are thought to directly
cause activating mutations in proto-oncogenes and loss of function
disruption of tumor suppressors [4,35]. Our data argue that effects
of carcinogens on selection of cells with oncogenic lesions, rather
than just on their occurrence, need to be considered as well.
Specifically, we demonstrate that while p53 loss appears to be
selectively neutral within unstressed hematopoiesis, irradiation
leads to a potent and sustained selection for cells with disrupted
p53 function.
Multiple Mechanisms Contribute to the Selection of Cells
with p53 Disruption
Our results implicate both protection from irradiation-induced
ablation and prevention from irradiation-induced loss of clono-
genic capacity in the selection for cells that lose p53 function
(Figure 8C). The resistance of p53-deficient hematopoietic cells to
irradiation-induced apoptosis was shown more than 10 years ago
[12–16]. However, the relevance of this immediate protection
towards long-term selective advantage in competitive contexts has
not been directly demonstrated. Indeed, many cell types fail to
show p53 dependence for long-term survival upon genotoxic stress
despite a clear protection by p53 disruption in short-term assays
[19,36]. Our results demonstrate that in addition to providing a
direct survival advantage, loss of p53 also protects hematopoietic
progenitors from severe irradiation-induced loss of clonogenic
capacity.
This preservation of clonogenic capacity is especially relevant
for the HSC compartment. We observe no significant loss of
phenotypic HSC within 48 h of irradiation, and yet limiting dilution
assays indicate that irradiation significantly reduces the numbers of
functional WT HSC. This reduction is consistent with a recent
report that irradiation induces hallmarks of senescence in an HSC-
enriched population [33]. In addition to the reduction in numbers
of functional stem and progenitor cells, irradiation appears to limit
clonal potential per cell. Importantly, the loss of p53 function
preserves both the numbers of functional stem/progenitor cells
and their fitness (functional capacity as measured in competitive
repopulation assays).
The Role of Selection for Ionizing Irradiation-Induced
Tumorigenesis
Homozygous p532/2 mice are highly prone to spontaneous T-
cell lymphomas [20,21]. While p53 heterozygous mice exhibit
much later onset and penetrance of malignancies, they rapidly
succumb to lymphomas following irradiation, and these lympho-
mas invariably lose the WT p53 allele [23]. One possible
explanation for the induction of p53 null lymphomas in p53
heterozygous mice is that irradiation selects for pre-existing or
irradiation induced p53 loss-of-heterozygosity events, thereby
increasing the target size for additional oncogenic mutations that
can cooperate with loss of p53 to promote tumor progression. On
the other hand, a more prevalent interpretation attributes the
carcinogenic effect of irradiation to the induction of new
oncogenic mutations [1]. Given the critical importance of p53 in
arresting/killing cells with oncogenic mutations [24], many
growth-promoting mutations would be expected to synergize with
p53 loss in driving abnormal cell expansion and proliferation, in
which case the selection for p53 mutation itself might be irrelevant.
Indeed, Evan and colleagues demonstrated that conditional
activation of p53 during irradiation has no effect on its tumor
suppressor function, while activating p53 2 wk after irradiation
results in strong suppression of lymphoma development. Since at
2 wk after irradiation the acute damage is resolved, the authors
concluded that the essential tumor suppressor function of p53
B220
+ lineages at 3 and 8 wk post-transplantation. Differences for DDp53 Mac1
+ groups and all Vector groups with or without irradiation were not
significant. (C) Recipient mice were sacrificed at 21 wk post-BM transplant, and percentages of GFP
+ cells determined in the BM and thymus. For BM,
GFP representation in the B220
+Mac1
neg (BM B220) or Mac1
+B220
neg (BM MAC1) populations is graphed. For thymus, the percentage of total
thymocytes expressing GFP is graphed. The ‘‘neg contr’’ data points are from mice that received no transplantation, which serve as negative controls
for GFP detection.
doi:10.1371/journal.pbio.1000324.g006
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Figure 7. Transplantation of non-irradiated competitors reverses the selective advantage conferred by p53 disruption following
irradiation. (A) BM was transduced with MiG-DDp53 and transplanted into 20 lethally irradiated recipients as in Figure 1. Initial infection efficiency
was 8.5%. Each of the recipients was transplanted with 1610
7 cells. Six weeks post-transplantation, blood was drawn for baseline analysis.
Subsequently, the mice were X-irradiated with a single 2.5 Gy dose (IR). Ten of the 20 mice then received transplantation via tail vein injection of 10
7
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activated oncogenes, while the p53-dependent elimination of cells
with radiation-induced DNA damage is dispensable [37].
Complementary experiments by Donehower and colleagues
demonstrated that inactivation of p53 2 wk post-irradiation leads
to promotion of lymphomas, virtually indistinguishable from
promotion of lymphomas by disruption of p53 prior to irradiation
[38], supporting the conclusions reached by Evan and colleagues.
Our studies have reached a different conclusion: p53-dependent
elimination of irradiation-damaged cells is actually tumor-
promoting. Since irradiation leads to elimination and functional
arrest of progenitors with intact p53 function, it selects for p53-
deficient clones. Thus, we conclude that the p53-dependent
elimination of cells following irradiation is important for
lymphomagenesis. The critical distinction of our study from those
of Evan and Donehower is that we employed models in which p53
is mutated in only a small fraction (instead of the majority) of cells.
This scenario more closely models tumorigenesis induced by
irradiation in WT animals. Starting with a small fraction of p53-
deficientcells allowed us to observe that while under normal
conditions disruption of p53 is selectively neutral, irradiation
endows p53 disrupted cells with a strong selective advantage,
driving potent and sustained selection for p53 disrupted cells in
stem and progenitor cell pools. The increased fraction of p53-
deficientcells should increase the probability that oncogenic events,
which are normally cleared through p53-dependent surveillance,
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Figure 8. Irradiation promotes p532/2 lymphomagenesis. (A) BM chimeric mice described in Figure 7B were followed for lymphoma or
leukemia development (10 mice/group). Mice were sacrificed when moribund, as in Figure 2D, and leukemia-free survival plotted. Leukemia-free
survival differences between irradiated chimeric mice with or without BM transplantation post-irradiation were not significant (p=0.39; logrank test).
(B) p532/2 GFP-Tg BM was transplanted into recipients that had been conditioned with 5 Gy irradiation. Recipients displayed .90% GFP
+ (p532/2)
hematopoiesis as assessed 6 wk post-transplant (unpublished data). Six weeks post-transplant, mice were sublethally irradiated (2.5 Gy; IR) or left
unirradiated (no IR), and leukemia-free survival is plotted (10 mice/group). Lymphoma/leukemia development was significantly delayed by irradiation
(log-rank test). For both (B) and (C), all lymphomas analyzed were CD4
+/CD8
+ or CD4
+ and expressed GFP (indicating their origin from the p532/2
GFP Tg BM; Figure S2 and unpublished data). (C) Model: p53 mutation confers partial resistance to the acute effects of ionizing irradiation and partial
protection from the loss of long-term clonogenic potential, leading to selection for hematopoietic cell clones with disrupted p53. Irradiation-induced
selection for p53 loss leads to an increased target size for secondary mutations (indicated by altered cell shape), which together with the loss of
critical guardian functions of p53 that normally eliminate cells with DNA damage or oncogenic mutations, can drive malignant transformation. The
resulting neoplasm may no longer be limited to the confines of normal progenitor cell niches.
doi:10.1371/journal.pbio.1000324.g008
whole BM cells (‘‘comp’’) from unirradiated mice (within an hour of irradiation). At 7 wk post-sublethal irradiation, peripheral blood was analyzed for
the expression of GFP in MAC
+ myeloid, B220
+ B lineage, CD4
+ T lineage, and CD8
+ T lineage cells. Note that in control experiments, similar
transplantation of non-irradiated competitors immediately after 2.5 Gy irradiation resulted in engraftment of transplanted BM, but with maintenance
of some host hematopoietis (Figure S8). The indicated p values are for t tests comparing means of difference in GFP percentages for baseline to 4 wk
post-irradiation between irradiated and control groups. (B) BM chimeric mice containing 2.5% GFP Tg p532/2 BM were generated as in Figure 3.
Each recipient mouse received a total of 4610
6 BM cells. Recipients were sublethally irradiated (2.5 Gy; IR) or left unirradiated (no IR) 6 wk after
transplantation. One group of 10 irradiated mice (IR+C) then received transplantation via tail vein injection of 10
7 whole BM cells from unirradiated
mice (within an hour post-irradiation). At 1 and 3 mo post-sublethal irradiation, peripheral blood was analyzed for the expression of GFP in the
indicated lineages as in (A). For all lineages, GFP percentages either between control and IR groups or between IR and IR+comp groups were
statistically significant with p values below ,0.0001 as determined by two-way ANOVA.
doi:10.1371/journal.pbio.1000324.g007
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unchecked to drive oncogenic transformation. Moreover, the
expansion of p53 progenitor clones should further promote
lymphoma development by augmenting genetic instability
[11,39–41], thus increasing the genetic diversity available to fuel
malignant evolution (Figure 8C).
Our results do not support the widely held presumption that
direct causation of oncogenic mutations alone is sufficient for the
carcinogenic effects of irradiation and instead argue for the
importance of selection. First, if direct causation of oncogenic
mutations were the only mechanism of irradiation-induced
oncogenesis, one would expect that irradiation should boost
lymphomagenesis in recipients of 100% p532/2 BM, as
oncogenic mutations (normally eliminated through p53-dependent
surveillance mechanisms) would be able to drive malignant
progression. When the majority of hematopoietic cells are
p532/2, the contribution of selection for p53 null cells is negated,
while the contributions of induced oncogenic mutations (normally
eliminated dependent on p53) should be maximal. Contrary to the
predominant role of mutagenesis and consistent with the
importance of selection, we observed that irradiation actually
delayed lymphoma development in mice with mostly p532/2
hematopoiesis (Figure 8B). Second, if the irradiation-induced
lymphomas in p532/2 chimeras were solely dependent on the
induction of oncogenic mutation, cooperating with p53 loss, these
mutations would be expected to drive abnormal proliferation
regardless of the status of competitor cells. However, this is not the
case: addition of non-irradiated competitor BM dramatically
inhibits the selective expansion of p53-deficientcells (Figure 7).
Still, irradiation does accelerate tumor development in p532/2
mice less than 7 d old (but not in adult p532/2 mice) [23], as well
as in the mouse model used by the Donehower group [38].
Moreover, co-transplantation of unirradiated BM failed to prevent
irradiation-promoted lymphomagenesis despite strongly inhibiting
selection for p53 mutant cells (Figure 8A), although the inhibition
of selection was substantially delayed in the T-cell lineage
(Figure 7B). Therefore, in some contexts irradiation can promote
p53-deficient tumorigenesis independent of altered selection for
p53 loss.
Additional Evidence for the Importance of Selection in
Carcinogenesis
Ultraviolet (UV) light exposure has been shown to increase the
numbers and size of p53 mutant clones in human skin [42] and to
induce the expansion of p53 mutant/Ras activated premalignant
cells in organotypic skin cultures [43]. The expansion of p53
disrupted clones in mouse skin required continued UV-B exposure
[44], contrasting with the stable selection for p53 disruption
following a single exposure to X-irradiation in our studies. Of
interest, conferring increased apoptosis resistance to skin cells
actually hampers the expansion of p532/2 clones and the
frequency of UV-induced skin cancers in mice [45]. Of course,
selection for p53 loss is not limited to contexts of initiation. Within
established tumors, chemotherapy leading to DNA damage and
anti-angiogenic therapy leading to hypoxia have each been shown
to potently select for p53 disruption [24,46,47].
Direct links between carcinogen exposure and causation of
oncogenic mutations have clearly been implicated in some
contexts. For example, the skin cancer-associated mutational
spectra in INK4A and p53 genes are specific to UV light-induced
mutagenesis [48–50]. On the other hand, the presence of an
initiating mutation is not sufficient for tumorigenesis unless the
mutation leads to clonal expansion, as the small target size of an
unselected mutant clone should substantially limit the chances for
acquisition of additional oncogenic events. Thus, even for UV
irradiation, where the evidence for direct causation of oncogenic
mutations is the strongest, both the mutagenic and selective
functions appear to be implicated in UV-induced carcinogenesis.
Notably, genetic alterations unique to ionizing radiation are not
evident in cancers associated with radiation exposure [1].
Of note, the loss of p53 is not the only oncogenic event that can
be selected by irradiation. While in the context of previous
irradiation p53 inhibition failed to provide a stable selective
advantage (Figure 6), cells that expressed the Notch1 mutant ICN
were strongly selected for within previously irradiated progenitor
cell pools [32]. Notably, co-transplantation of non-irradiated
hematopoiesis potently inhibits both selection for ICN expressing
cells and the resulting leukemogenesis. The ability of healthy WT
competitors to limit expansion of oncogenically mutated cells has
also been demonstrated in other contexts of genetic or chemical
impairment of cell proliferation [51,52]. Thus, the expansion of an
initiated clone requires both conditions of reduced fitness within a
progenitor pool and the presence of cells with oncogenic mutations
adaptive or resistant to the particular fitness-reducing context.
In summary, while current paradigms primarily focus on how
mutations in key genes controlling cell proliferation and survival
contribute to the evolution of cancer, the data presented here,
together with previous studies, indicate that greater focus on how
carcinogenic contexts impact on selection of cells with oncogenic
events such as p53 disruption may be critical for understanding,
preventing, and perhaps even treating cancers.
Materials and Methods
Ethics Statement
The University Colorado Denver School of Medicine Animal
Care and Use Committee approved all mouse experiments.
Retroviral Constructs and Infections
MiG constructs expressing DDp53 (‘‘dimerization domain’’ of
p53) have been previously described [51]. Viral particles were
assembled using yNX-Eco packaging cells as previously described
[51]. Freshly isolated BM cells were transduced with retrovirus
containing yNX-Eco supernatants in non-adhesive six-well plates
using the spin-fection technique (centrifugation at 910 g for 1.5 h
in the presence of 8 mg/ml polybrene). Cells were then washed
once with PBS and transplanted into recipient mice.
BM Transplantations and Irradiation
Mice were starved the night before irradiation to reduce
intestinal irradiation damage. BM transplant recipients were
lethally irradiated with two 5 Gy doses separated by 3–4 h (10
Gy combined) using an X-ray source (RadSource RS2000
irradiator). A single 2.5 Gy dose was used for sublethal irradiation.
Donor BM was transplanted via tail vein injections.
CFU Assays
BM was harvested from the femurs and tibiae of non-irradiated
or irradiated (48 h previously at 2.5 Gy) WT or p53
2/2 Balb/c
donors. Live cells were counted by propidium iodide exclusion
using the Cell Lab Quanta SC cytometer (in triplicate). Pre-B
CFU (CFU-B) and CFU-GEMM assays were performed with
M3630 and M3434 media (Stem Cell Technologies, Vancouver,
British Columbia, Canada), respectively, according to the
manufacturer’s instructions. Colonies were counted 7 d (CFU-B)
or 12 d (CFU-GEMM) later, and the numbers of CFU per mouse
(both femurs and tibiae) were calculated. For CFU-S, recipient
mice were irradiated to sufficiently suppress endogenous CFU-S
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with varied numbers (6610
4–1.3610
6) of live cells. Recipients
were euthanized 14 d later, and spleens were harvested and fixed
in Bouin’s fixative overnight. CFU-S were enumerated the
following day and the number of CFU-S per mouse was calculated
based on the number of cells that had been harvested from each
donor. Several recipients of irradiated WT BM died prior to
spleen harvest, presumably due to hematopoietic failure.
Mice
Balb/c mice were purchased from the National Cancer Institute
or generated by in-house breedings. p532/2 mice [21] were
purchased from Jackson Labs. GFP Tg mice were the generous gift
of the Kappler/Marrack lab [29]. GFP Tg and p532/2 animals
were backcrossed together into the Balb/c background for 10211
generations.
Tissue Harvests and Flow Cytometric Analyses
Single-cell suspensions of hemolysed BM, spleen, or peripheral
blood were washed in PBS containing 1% BSA (BSA-PBS) and
resuspended in BSA-PBS plus 5% supernatant from hybridoma
cells producing the 2.4G2 monoclonal antibody against the Fc
receptor (to block Fc receptors on hematopoietic cells, which
nonspecifically bind antibodies). 10
5 to 10
6 cells were stained in
20 ml of antibody solution (1:200 dilution of each antibody) for
30 min on ice. Cells were washed once with 1 ml of BSA-PBS and
resuspended in 400 ml of BSA-PBS for flow cytometric analysis.
The following PharMingen (San Diego, California, USA)
antibodies against mouse proteins were used: phycoerythrin
(PE)-linked anti-B220, PE-anti-Ter119, PE-anti-GR-1, PE-anti-
CD3, PE-anti-CD4, and PE-anti-CD8 (together, these PE-linked
antibodies constitute the ‘‘Lin’’ stain to gate out lineage committed
progenitors and mature cells), and allophycocyanin (APC)-linked
anti-B220. PE-Cy7-linked streptavidin, biotin-anti-CD93 (AA4.1),
PE-Cy7-anti-CD11b (Mac1), and PE-anti-CD48 were purchased
from eBioscience (San Diego, California, USA). Pacific Blue-
linked streptavidin was purchased from Invitrogen (Carlsbad,
California, USA), and APC-anti-CD150 was from BioLegend (San
Diego, California, USA). Fluorescence was detected with CyAn
(DAKO, Carpinteria, California, USA) or Cell Quanta SC MPL
(Beckman Coulter, Allendale, New Jersey, USA) cytometers.
Automated haematocrit analysis of peripheral tail vein blood
was performed using a Cell-Dyn 1700 System (Abbott, Abbott
Park, Illinois, USA).
Analyses of Lymphoma and Leukemia Development
Transplanted mice were monitored for disease development, as
judged by increasing percentages of GFP
+ cells (invariably CD4
+/
CD8
+ or CD4
+) with blast morphology in peripheral blood of
transplanted animals, as well as symptoms, such as reduced
mobility, hunching, and labored breathing. Moribund animals
were sacrificed and examined for thymoma or leukemia
development, as well as the dissemination of the lymphoma to
spleen and BM. The expression of lineage markers (CD4, CD8,
B220, and Mac1) on GFP
+ leukemia and lymphoma cells was
assessed by antibody staining and flow cytometry.
Statistical Analysis
Statistical analyses were performed using Prizm 4 software from
GraphPad. GFP percentage data were transformed with the
arcsine transformation prior to analysis. Unless otherwise
specified, p values represent the results of unpaired two-tailed t
tests. In cases when an F test indicated different variances between
the groups, Welsh’s correction was applied. Kaplan-Meier survival
curves were used to calculate statistical significance for differences
in leukemia development (using the Logrank test). Limiting
dilution analysis for the calculation of HSC frequencies and
statistical significance was performed using the L-Calc software
package from Stem Cells. All presented data are representative of
at least two independent experiments. N/S indicates p values
greater than 0.05, * between 0.05 and 0.01, ** between 0.01 and
0.001, and *** below 0.001.
Supporting Information
Figure S1 Examples of flow cytometric gating strategies
for determination of GFP expression in specific lineages
in peripheral blood. (A) Non-irradiated DDp53 mosaics. (B)
Irradiated DDp53 mosaics, 2 wk post-irradiation.
Found at: doi:10.1371/journal.pbio.1000324.s001 (0.03 MB PDF)
Figure S2 Lymphomas and leukemias that develop in
p532/2GFP Tg:WT chimeras are from p532/2GFP
+
donor BM. Mice from the experiments shown in Figures 2 and 8
were followed for the development of hematopoietic malignancies.
All sacrificed mice exhibited clear signs of thymomas or leukemias.
Mice exhibited greatly enlarged thymi and/or spleens almost
entirely composed of GFP
+ blasted cells (either CD4
+CD8
+ or
CD4
+). An example of flow cytometric analysis of cells from the
thymus, peripheral blood, and BM of a moribund mouse in the IR
group (from the experiment presented in Figure 8A) is shown. The
CD4
+CD8
+ GFP
+ lymphoma in this example constitutes the
majority of cells in the thymus and peripheral blood but only a
small fraction of BM cells (typical of a lymphoma). All other
sacrificed moribund mice exhibited a similar development of
GFP
+ lymphomas or leukemias.
Found at: doi:10.1371/journal.pbio.1000324.s002 (0.35 MB PDF)
Figure S3 Irradiation reduces spleen and BM cellular-
ity. Mice transplanted with MiG (Vector) or MiG-DDp53
transduced BM (as in Figure 1) were sublethally irradiated 6 wk
after BM transplantation and sacrificed 48 h later. Spleen weights
and tibia cellularity were determined.
Found at: doi:10.1371/journal.pbio.1000324.s003 (0.02 MB PDF)
Figure S4 X-irradiation reduces the numbers of BM
B220
+ cells, leading to selection of p532/2 cells. BM
chimeric mice from the experiments described in Figure 3,
containing about 5% GFP Tg BM (WT) or 5% GFP Tg p532/2
BM, were killed 48 h post-irradiation and analyzed. Left: numbers
of B220
+ cells per one tibia; right: percentage of GFP
+ cells among
B220
+ lineage. Statistical analyses were performed as in Figure 3.
Found at: doi:10.1371/journal.pbio.1000324.s004 (0.02 MB PDF)
Figure S5 Irradiation results in selection for p53
mutation in pro-B cell pools, but not phenotypic HSC-
enriched pools, within 48 h. BM chimeric mice were from the
experiments described in Figure 3, containing about 5% GFP Tg
BM (GFP) or 5% GFP Tg p532/2 BM. At 48 h post-2.5 Gy
irradiation, the mice were euthanized, and GFP expression in the
BM was analyzed in the indicated populations by antibody
staining and flow cytometry: (A) pro-B cell pools
(B220
+CD93
+CD43
+Mac1
neg) and (B) HSC pools (Lin
negCD48-
negCD150
+). Percentages and numbers of GFP
+ cells within the
indicated lineages are graphed. Statistical analyses were performed
as in Figure 3.
Found at: doi:10.1371/journal.pbio.1000324.s005 (0.02 MB PDF)
Figure S6 Examples of flow cytometric gating strate-
gies for the analyses of pro-B, pre-B, myeloid, and HSC-
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shown for the quantitation of GFP
+ cells within the indicated
populations used for Figures 3 and S5. (A) WT chimeric BM
without irradiation (mock). (B) WT chimeric BM, 48 h post-
irradiation. (C) p532/2 chimeric BM without irradiation. (D)
p532/2 chimeric BM, 48 h post-irradiation. For (A–D), the
percentages of GFP
+ and GFP
neg gates within the myeloid
(Mac1
+), pre-B (B220
+CD93
+CD43
negMac1
neg), and pro-B
(B220
+CD93
+CD43
+Mac1
neg) cell compartments are indicated.
(E) Examples of flow profiles and gating strategies for the
Lin
negCD48
negCD150
+ HSC-enriched population. The percent-
ages of HSC-enriched cells (elliptical R3 gate, relative to total live
cell gate) and of GFP
+ cells within the HSC-enriched gate are
indicated. Arrows indicate the gating strategy.
Found at: doi:10.1371/journal.pbio.1000324.s006 (0.25 MB PDF)
Figure S7 Irradiation selectively ablates the CD4
+CD8
+
double-positive population in the thymus. Thymocytes
from mice described in Figure 3 were stained with antibodies
against CD4 and CD8 and analyzed by flow cytometry.
Representative flow profiles are shown, with percentages of cells
in sub-populations indicated.
Found at: doi:10.1371/journal.pbio.1000324.s007 (0.03 MB PDF)
Figure S8 Transplantation of BM after 2.5 Gy irradia-
tion results in chimeric engraftment. Balb/c mice (n=5)
were irradiated at 2.5 Gy and then transplanted with 10
7 whole
BM cells from a GFP-Tg donor mouse. Peripheral blood was
analyzed 5 mo later for GFP
+ cell contributions to myeloid, B-cell,
and T-cell lineages. GFP percentages were less than 1% in all
negative controls (untransplanted Balb/c mice), and the percent
GFP
+ within the B220
+, Mac-1
+, CD4
+, and CD8
+ gates were
86.9%, 98.5%, 90.2%, and 92.8%, respectively, from a GFP Tg
mouse (the positive control for GFP detection), indicating that
significant GFP
neg hematopoiesis was detected in recipient mice.
Found at: doi:10.1371/journal.pbio.1000324.s008 (0.01 MB PDF)
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